An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

US police have confirmed that Brian Thompson was fatally shot outside an investor conference by a masked assailant.

Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.

Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals to develop BMX-502.

Takeda has signed an agreement to receive an exclusive global licence from Keros Therapeutics for elritercept.

Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.

Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.

Olema Oncology and Novartis have signed a clinical trial collaboration and supply agreement for a Phase III trial in metastatic breast cancer.

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.

J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.

The research team at UQ has secured a grant of $344,000 from the National Foundation for Medical Research and Innovation.